In addition, the expression of OX40L on CD19+ B cells and CD14+ monocytes did not significantly differ between patients with MG at baseline, in remission, and in relapse (P > 0.05) (Table 3, Figures 2(a), 2(c), and 2(d)). This evidence concerns the gene CD19 and myasthenia gravis.